This class of drugs improves glycaemic control without hypoglycaemia and achieves substantial weight loss by addressing appetite, likely representing the most significant advance in the care of people living with metabolic disease this century [18, 19]
Dhillon, K
A state-licensed physician reviews your questionnaire, completes a full clinical evaluation, and (where required by state law) conducts a live video or phone consultation to answer questions and confirm suitability
They actually test for 310 different chemicals that can be found in coffee to make sure Purity Coffee is free of these
Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications
